Skeletal adverse effects with aromatase inhibitors in early breast cancer: Evidence to date and clinical guidance

25Citations
Citations of this article
57Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aromatase inhibitors (AIs) are routinely used in the adjuvant treatment of women with hormone receptor-positive early breast cancer. Patients who receive AIs have an increased risk of bone loss and arthralgia compared with those treated with tamoxifen. In addition to the effects of AIs, the population of women with early breast cancer has a high prevalence of 25-hydroxyvitamin D (25(OH)D) insufficiency. In our experience 88% of patients had concentrations lower than 30 ng/ml. Vitamin D supplementation should be adapted to the baseline concentration. Another relevant finding in our research program was the close relationship between 25(OH)D levels and intensity of AI-related arthralgia (AIrA). A target concentration of 40 ng/ml 25(OH)D may prevent development of AIrA. We also demonstrate that AIrA is genetically determined: single nucleotide polymorphisms located in genes encoding key factors for the metabolism of estrogens and vitamin D (CYP17A1, VDR, and CYP27B1) are associated with self-reported arthralgia during AI therapy. We recommend establishing an individualized protocol of bone-health surveillance based on baseline and evolutionary clinical variables. © 2015, SAGE Publications. All rights reserved.

Cite

CITATION STYLE

APA

Servitja, S., Martos, T., Garrigos, L., Rodriguez Sanz, M., Garcia Giralt, N., Prieto Alhambra, D., … Tusquets, I. (2015). Skeletal adverse effects with aromatase inhibitors in early breast cancer: Evidence to date and clinical guidance. Therapeutic Advances in Medical Oncology. https://doi.org/10.1177/1758834015598536

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free